Near-Patient Molecular Solutions Market Is Expected To Offer Substantial Growth Opportunities, Reaching $7.17 Billion By 2030

 

What Is The Expected Valuation Of The Near-Patient Molecular Solutions Market In The Upcoming Years, And How Quickly Is It Set To Grow?
 The near-patient molecular solutions market size has grown strongly in recent years. It will grow from $4.54 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to expansion of molecular diagnostic techniques, demand for rapid test turnaround times, decentralization of laboratory services, growth in outpatient diagnostic settings, adoption of portable diagnostic instruments.
 
 The near-patient molecular solutions market size is expected to see strong growth in the next few years. It will grow to $7.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising demand for home and remote testing solutions, technological advancements in miniaturized molecular platforms, expansion of infectious disease surveillance, integration with digital health ecosystems. Major trends in the forecast period include increasing adoption of point-of-care molecular testing devices, rising demand for rapid infectious disease diagnostics, growing integration of portable PCR platforms, expansion of decentralized diagnostic infrastructure, enhanced focus on near-patient testing accuracy.
 
 Claim Your Free Report Sample Today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=30333&type=smp
 
 Which Major Drivers Are Accelerating Expansion Within The Near-Patient Molecular Solutions Market?
 Growing demand for home-based point-of-care devices is expected to propel the growth of the near patient molecular solutions market going forward. Home‑based point‑of‑care devices are diagnostic testing systems that patients or non‑laboratory users operate at or near their home, enabling sample collection, analysis, or result reading outside a conventional central laboratory setting and in or close to the place of care. The growing demand for home‑based point-of-care devices is increasing due to the rising consumer preference for convenient, rapid, and accessible health monitoring outside traditional healthcare settings. Near-patient molecular solutions support the home-based point-of-care devices by providing accurate, rapid, and portable molecular diagnostics that can be reliably used outside traditional laboratory settings. For instance, in February 2023, the US Food & Drug Administration (FDA), a US-based government agency, reported in its 2023 COVID-19 testing update that there was one Emergency Use Authorization (EUA) for a molecular prescription at-home test, two EUAs for antigen prescription at-home tests, 26 EUAs for antigen over-the-counter (OTC) at-home tests, and four EUAs for molecular OTC at-home tests. Therefore, growing demand for home-based point-of-care devices is driving the growth of the near-patient molecular solutions market.
 
 Which Segments Are Expected To Shape The Future Direction Of The Near-Patient Molecular Solutions Market?
 The near-patient molecular solutions market covered in this report is segmented — 
 
 1) By Product Type: Infectious Diseases Testing Kits, Urinalysis Testing Kits, Tumor Or Cancer Markers, Pregnancy And Fertility, Hematology Testing Kits, Glucose Monitoring Kits, Drugs-Of-Abuse Testing Kits, Coagulation Monitoring Kits, Cardiometabolic Monitoring Kits, Other Product Types
 2) By Technology: Polymerase Chain Reaction (PCR)-Based, Genetic Sequencing-Based, Hybridization-Based, Microarray-Based
 3) By End-User: Hospitals And Clinics, Ambulatory Care Centers, Research Laboratories, Home Care Settings, Other End-Users
 
 Subsegments:
 1) By Infectious Diseases Testing Kits: Hepatitis Testing Kits, Human Immunodeficiency Virus Testing Kits, Influenza Testing Kits, COVID-19 Testing Kits
 2) By Urinalysis Testing Kits: Protein Testing Kits, Glucose Testing Kits, Ketone Testing Kits, Nitrite Testing Kits
 3) By Tumor Or Cancer Markers: Prostate-Specific Antigen Testing Kits, Carcinoembryonic Antigen Testing Kits, Cancer Antigen 125 Testing Kits, Alpha-Fetoprotein Testing Kits
 4) By Pregnancy And Fertility: Ovulation Testing Kits, Early Pregnancy Testing Kits, Digital Pregnancy Testing Kits, Home Fertility Monitoring Kits
 5) By Hematology Testing Kits: Complete Blood Count Testing Kits, Hemoglobin Testing Kits, White Blood Cell Count Testing Kits, Platelet Count Testing Kits
 6) By Glucose Monitoring Kits: Self-Monitoring Blood Glucose Kits, Continuous Glucose Monitoring Kits, Non-Invasive Glucose Testing Kits, Disposable Glucose Test Strips
 7) By Drugs-Of-Abuse Testing Kits: Urine Drug Testing Kits, Saliva Drug Testing Kits, Hair Drug Testing Kits, Blood Drug Testing Kits
 8) By Coagulation Monitoring Kits: Prothrombin Time Testing Kits, International Normalized Ratio Testing Kits, Activated Partial Thromboplastin Time Testing Kits, D-Dimer Testing Kits
 9) By Cardiometabolic Monitoring Kits: Cholesterol Testing Kits, Triglyceride Testing Kits, Low-Density Lipoprotein Testing Kits, High-Density Lipoprotein Testing Kits
 10) By Other Product Types: Allergy Testing Kits, Thyroid Function Testing Kits, Vitamin Deficiency Testing Kits, Liver Function Testing Kits
 
 Which Trend Shifts Are Redefining Opportunities In The Near-Patient Molecular Solutions Market?
 Major companies operating in the near-patient molecular solutions market are focusing on incorporating technological advancements such as isothermal nucleic acid amplification to enhance testing efficiency, portability, and diagnostic accuracy. Isothermal nucleic acid amplification is an advanced molecular diagnostic technology that amplifies target nucleic acid sequences at a constant temperature, eliminating the need for thermal cycling as in conventional polymerase chain reaction (PCR), thereby enabling rapid, sensitive, and compact molecular testing. For instance, in June 2023, Cue Health Inc., a US-based healthcare technology company specializing in molecular diagnostics, received FDA marketing authorization for the Cue COVID-19 Molecular Test, an isothermal amplification-based diagnostic device designed for at-home and point-of-care detection of SARS-CoV-2 RNA. The system features a single-use cartridge, a Bluetooth-enabled reader, and a mobile app interface that guides users through testing and delivers molecular results in about 20 minutes. The Cue COVID-19 molecular test improves access to accurate molecular-level diagnostics, reduces turnaround time, and supports real-time health decision-making outside traditional laboratory environments.
 
 Who Are The Companies Setting The Competitive Benchmark In The Near-Patient Molecular Solutions Market?
 Major companies operating in the near-patient molecular solutions market are Bosch Healthcare Solutions GmbH, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., bioMérieux SA, Sysmex Corporation, QuidelOrtho Corporation, QIAGEN NV, DiaSorin SpA, OraSure Technologies Inc., Molbio Diagnostics Pvt Ltd, Cue Health Inc., Biocartis Group NV, Vela Diagnostics Pte Ltd, Co-Diagnostics Inc., Hyris Ltd, Genedrive plc. 
 
 Get Your In-Depth Near-Patient Molecular Solutions Market Report Now:
 https://www.thebusinessresearchcompany.com/report/global-near-patient-molecular-solutions-market-report
 
 Which Region Currently Accounts For The Largest Share Of The Near-Patient Molecular Solutions Market?
 North America was the largest region in the near-patient molecular solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the near-patient molecular solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company